Bionano Genomics Files 2024 10-K
Ticker: BNGO · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1411690
| Field | Detail |
|---|---|
| Company | Bionano Genomics, Inc. (BNGO) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, biotechnology
TL;DR
BNGO filed its 2024 10-K. Check financials for FY24.
AI Summary
Bionano Genomics, Inc. filed its 2024 10-K on March 31, 2025, reporting its fiscal year ended December 31, 2024. The filing details the company's financial performance and operational activities, including information on its laboratory analytical instruments business. Specific financial figures and operational metrics for the fiscal year 2024 are presented within the report.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Bionano Genomics' financial health and strategic direction for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — The company operates in the highly competitive and rapidly evolving biotechnology sector, which carries inherent risks related to product development, market adoption, and regulatory approvals.
Key Numbers
- 0.1 — Asset Impairment Charges (Indicates a charge related to asset impairment for the fiscal year.)
- 0.0166666666666667 — Goodwill Impairment Loss (Represents a loss recognized from goodwill impairment.)
- 0.0167 — Selling, General and Administrative Expense (A component of the company's operating expenses.)
Key Players & Entities
- Bionano Genomics, Inc. (company) — Filer of the 10-K report
- 2024-12-31 (date) — Fiscal year end date for the report
- 2025-03-31 (date) — Filing date of the 10-K
- 9540 TOWNE CENTRE DRIVE SUITE 100 SAN DIEGO CA 92121 (address) — Company's business and mailing address
- 001-38613 (other) — SEC file number
FAQ
What was Bionano Genomics' total revenue for the fiscal year ended December 31, 2024?
The provided text does not explicitly state the total revenue for the fiscal year ended December 31, 2024. It focuses on expense categories and other financial metrics.
Did Bionano Genomics report any acquisitions during the fiscal year 2024?
The filing mentions 'bngo:acquisition' as a tag, suggesting that acquisitions are a relevant aspect of the company's activities, but specific details or dollar amounts are not provided in this excerpt.
What is the company's primary industry classification?
Bionano Genomics, Inc. is classified under 'LABORATORY ANALYTICAL INSTRUMENTS [3826]'.
When was Bionano Genomics, Inc. incorporated?
The company was incorporated in Delaware ('DE').
What are some of the key expense categories mentioned in the filing?
Key expense categories mentioned include 'AssetImpairmentCharges', 'GoodwillImpairmentLoss', 'OtherNonoperatingIncomeExpense', and 'SellingGeneralAndAdministrativeExpense'.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Bionano Genomics, Inc. (BNGO).